Head-to-head · WeighScore
MultiMedRx vs Spry
The verdict
MultiMedRx takes it — 57.6/100 to 56.8/100, but only just.
MultiMedRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MultiMedRx is a LegitScript-certified telehealth platform with physical offices in Newport Beach, CA and Reno, NV. Spry is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | MultiMedRx | Spry |
|---|---|---|
| WeighScore | 57.6/100 | 56.8/100 |
| Grade | C | C |
| Scorecard rank | #393 | #408 |
| Semaglutide | Not disclosed | $199/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $299/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #393 · C
Strengths
- Legal entity disclosed (MMRX MultiMedRx LLC) — uncommon transparency
- Two physical addresses listed: Newport Beach, CA and Reno, NV
- LegitScript seal present
- Features brand-name GLP-1s (Ozempic, Wegovy, Zepbound) — rare in a mostly compounded-only field
- Broader cardiometabolic menu (metformin, testosterone, HRT) alongside GLP-1
Where it loses points
- No Mounjaro or Foundayo in the brand-name lineup (only Ozempic, Wegovy, Zepbound)
- Monthly GLP-1 pricing isn't published — gated behind the consultation
- $100 consultation fee adds friction; many peers bundle it into the medication price
- Per-state availability not listed; only CA and NV offices disclosed
- Whether compounded GLP-1 is offered isn't clear — verify during intake
Graded #408 · C
Strengths
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
Where it loses points
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.